PALATIN TECHNOLOGIES INC (PTN)
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
$5.30+1.53%
Close 2026-11-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
QuarterlyIQ Insights · PTN
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance is holding in the top half of its industry — the reason to own it looks intact.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | -81.7% |
| Our one-year growth estimate | diamond | -28.9% |
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
No outside relationship met the current evidence threshold.
Based on historical daily prices through 2026-11-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Growth built into the price is above our model estimate.
The price assumes 52.8 percentage points less one-year growth.
The one-year revenue growth assumption on Valuation.
Elevated risk of a next-quarter earnings miss: this name is a smaller-cap name (higher miss base rate) and has erratic recent earnings surprises. A fundamental tilt, not a price call.
Model as of 2026-11-04 · Compared with 65 industry peers
PTN — legal / regulatory event — Notice
Dated 2026-05-18
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. On May 18, 2026, Palatin Technologies, Inc. (the “Company”), acting pursuant to authorization from its Board of Directors, provided notice to the NYSE American LLC (the “NYSE”) that it intends to voluntarily withdraw the listing of its common stock, par value $0.01 per share (the “common stock”), from the NYSE and transfer the listing of its common stock to the Nasdaq Capital Market (the “Nasd…
Why it matters: The figures can show if revenue rises and losses fall while the company still uses a lot of cash.
Watch forOn November 13, revenue is at least $8.83M. Operating loss is no worse than $1.58M. Cash from operations is less negative than -$4.4M.
Also watch forOn November 13, revenue is below $116K, operating loss is worse than -$7.3M, or cash from operations is -$4.8M or worse.
Why it matters: An IND filing would move Palatin's oral drug toward human testing. A delay would slow this program.
Supportive ifPalatin files an IND for its next-generation oral MC4R drug by June 30, 2027.
Worry ifPalatin reports the filing will occur after H1 2027, or names no filing by June 30, 2027.
Why it matters: Closing the raise would confirm that the planned cash came in. No close would leave delivery unclear.
Supportive ifA company filing or report confirms the offering closed. It raised about $15.8M in gross proceeds.
Worry ifA company filing says the offering was canceled or raised much less than about $15.8M.
Why it matters: Trial plans can show if the programs check for side effects and effects beyond their target, including skin color changes.
Watch forPalatin reports a trial plan that tracks side effects and skin color changes. It reports no major safety issue.
Also watch forPalatin reports a serious safety issue, a trial pause, or plans that do not track side effects or skin color changes.
We watch for confirming and disproving signals on each item. Resolutions are found automatically where possible and checked by hand for unclear cases. Last 90 days shown.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$404 on $10,000 · ±4.0% | How much price usually moves either way. |
| Bad day | $1,011 loss on $10,000 · 10.1% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $8,296 loss on $10,000 · 83.0% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Why it matters: A filed IND would mark progress toward testing Palatin's weekly obesity drug in people. A delay would push back that step.
Supportive ifPalatin files an IND for its once-weekly MC4R drug by December 31, 2026.
Worry ifPalatin says the IND filing has slipped past Q4 2026, or reports no filing by year-end.